Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T18:30:38.427Z.
Calculation as of: 2026-10-06T18:30:38.427Z.
Quote observation: 2026-10-06T18:30:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5a667a199b47e7e336467208d2f6772290b800d1a0ab6507ee3a182ebbb9f075
PE RATIO
N/A
BGM Group Ltd.
Market Cap
$122.81M
PE Ratio
N/A
| NAME | MARKET CAP | PE RATIO |
|---|---|---|
| BGM Group Ltd. (BGM) | $122.81M | N/A |
| Spruce Biosciences, Inc. (SPRB)vs › | $119.23M | N/A |
| LENZ Therapeutics, Inc. (LENZ)vs › | $118.68M | N/A |
| Tenaya Therapeutics, Inc. (TNYA)vs › | $120.50M | N/A |
| enGene Holdings Inc. (ENGN)vs › | $120.92M | N/A |
| Seer, Inc. (SEER)vs › | $121.23M | N/A |
| Cibus, Inc. (CBUS)vs › | $122.13M | N/A |
| Coya Therapeutics, Inc. (COYA)vs › | $116.98M | N/A |
| TuHURA Biosciences, Inc. (HURA)vs › | $125.45M | N/A |
| Genelux Corporation (GNLX)vs › | $114.34M | N/A |
Trailing P/E
N/A
Forward P/E
N/A
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
